Oct 08, 2020 9:00am EDT CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference
Sep 10, 2020 4:05pm EDT CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit
Aug 26, 2020 8:30am EDT CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
Aug 24, 2020 9:00am EDT CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
Aug 13, 2020 4:03pm EDT CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update